The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Open accessAbstract
BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk of diabetes. RESULTS: Variants in PCSK9 and HMGCR were associated with nearly identical protective effects on the risk of cardiovascular events per decrease of 10 mg per deciliter (0.26 mmol per liter) in the LDL cholesterol level: odds ratio for cardiovascular events, 0.81 (95% confidence interval [CI], 0.74 to 0.89) for PCSK9 and 0.81 (95% CI, 0.72 to 0.90) for HMGCR. Variants in these two genes were also associated with very similar effects on the risk of diabetes: odds ratio for each 10 mg per deciliter decrease in LDL cholesterol, 1.11 (95% CI, 1.04 to 1.19) for PCSK9 and 1.13 (95% CI, 1.06 to 1.20) for HMGCR. The increased risk of diabetes was limited to persons with impaired fasting glucose levels for both scores and was lower in magnitude than the protective effect against cardiovascular events. When present together, PCSK9 and HMGCR variants had additive effects on the risk of both cardiovascular events and diabetes. CONCLUSIONS: In this study, variants in PCSK9 had approximately the same effect as variants in HMGCR on the risk of cardiovascular events and diabetes per unit decrease in the LDL cholesterol level. The effects of these variants were independent and additive. (Funded by the Medical Research Council and the National Heart, Lung, and Blood Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As an extension of MR, drug target MR has emerged as efficient way to estimate therapeutic potential by using genetic variants in genes encoding drug targets (referred to as cis variants) to mimic the actions of drugs.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, these observations are supported by data from a recent mendelian randomization study in which variants in PCSK9 and variants in HMGCR were associated with nearly identical lower risks of cardiovascular events per unit reduction in LDL cholesterol.29”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [29]
In the citing paper
“mendelian randomisation studies 8,[19][20][21] of genetic polymorphisms that mimic the effects of statins, ezetimibe, or PCSK9 inhibitors suggest that lifelong reductions in LDL cholesterol, irrespective of the mechanism, are associated with an increased risk of diabetes.”
In the citing paper
“Mendelian randomisation analyses 8,20,21 have shown that genetically determined loss of function of PCSK9 is associated with an increased risk of incident diabetes, but clinical trials of PCSK9 inhibitors have shown no such effect.9”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationMulti-Ethnic Study of Atherosclerosis: Objectives and Design
Bild, D. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf113 · Cited by 3,942
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Willer (2013) · doi:10.1038/ng.2797 · Cited by 2,983
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citation
Cited by
Sorted by citations
Items 301–400 of 747
Huang, X., Zhang, T., Guo, P., Gong, W., Zhu, H., Zhao, M., & Yuan, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1164387 · Cited by 23
Unexplained reciprocal regulation of diabetes and lipoproteins
Higuchi, S., Izquierdo, M. C., & Haeusler, R. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000521 · Cited by 20
Ganda, O. P., Plutzky, J., Sanganalmath, S. K., Bujas‐Bobanovic, M., Koren, A., Mandel, J., Letierce, A., & Leiter, L. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13384 · Cited by 20
LDL cholesterol: How low to go?
Packard, C. J. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.12.011 · Cited by 20
New Insights in the Control of Low-Density Lipoprotein Cholesterol to Prevent Cardiovascular Disease
Katzmann, J. L., & Laufs, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1159-z · Cited by 19
Carcamo‐Orive, I., Henrion, M., Zhu, K., Beckmann, N. D., Cundiff, P., Moein, S., Zhang, Z., Alamprese, M. L., D’Souza, S. L., Wabitsch, M., et al. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008491 · Cited by 18
Chen, T., Wang, Z., Xie, J., Xiao, S., Li, W., & Liu, N. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.05.033 · Cited by 20
Petrazzini, B. O., Forrest, I. S., Rocheleau, G., Vy, H. M. T., Márquez‐Luna, C., Duffy, Á., Chen, R. K., Park, J. K., Gibson, K., Goonewardena, S. N., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01791-x · Cited by 20
A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Chen, B., Shi, X., Cui, Y., Hou, A., & Zhao, P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190809094203 · Cited by 22
Mansi, I. A., Sumithran, P., & Kinaan, M. (2023) · BMJ · doi:10.1136/bmj-2022-071727 · Cited by 20
Small, A. M., Huffman, J. E., Klarin, D., Lynch, J. A., Assimes, T., DuVall, S., Sun, Y. V., Shere, L., Natarajan, P., Gaziano, M., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239752 · Cited by 19
Can we revive CETP-inhibitors for the prevention of cardiovascular disease?
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000854 · Cited by 19
Yuan, S., Titova, O. E., Zhang, K., Chen, J., Li, X., Klarin, D. M., Åkesson, A., Damrauer, S. M., Program, V. M. V., & Larsson, S. C. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead056 · Cited by 19
PCSK9 and carbohydrate metabolism: A double-edged sword
Filippatos, T. D., Filippas-Ntekouan, S., Pappa, E. T., Panagiotopoulou, T., Tsimihodimos, V., & Elisaf, M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i7.311 · Cited by 19
Lorenzatti, A. J., Eliaschewitz, F. G., Chen, Y., Fialkow, J. A., Lu, J., Baass, A. W., Monsalvo, M. L., Hsu, H., Somaratne, R. M., & Ge, J. (2018) · Clinical Cardiology · doi:10.1002/clc.23018 · Cited by 18
PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives
Fitzgerald, G., & Kiernan, T. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1497975 · Cited by 21
Cyr, Y., Lamantia, V., Bissonnette, S., Burnette, M., Besse‐Patin, A., Demers, A., Wabitsch, M., Chrétien, M., Mayer, G., Estall, J. L., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14721 · Cited by 20
Arsenault, B. J., Perrot, N., & Puri, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1110 · Cited by 21
Genome-wide association study for circulating metabolic traits in 619,372 individualsPreprint
Tambets, R., Kronberg, J., van der Graaf, A., Jesse, M., Abner, E., Võsa, U., Rahu, I., Taba, N., Kolde, A., Yarish, D., et al. (2024) · medRxiv · doi:10.1101/2024.10.15.24315557 · Cited by 19
Low cholesterol states: clinical implications and management
Gill, P. K., & Hegele, R. A. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204932 · Cited by 19
Das, A. K., Saboo, B., & Unnikrishnan, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s294842 · Cited by 21
Pharmacometabolomics for the Study of Lipid-Lowering Therapies: Opportunities and Challenges
Gianazza, E., Brioschi, M., Iezzi, A., Paglia, G., & Banfi, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043291 · Cited by 18
Characterizing the genetic architecture of drug response using gene-context interaction methods
Sadowski, M., Thompson, M., Mefford, J., Haldar, T., Oni‐Orisan, A., Border, R., Pazokitoroudi, A., Cai, N., Ayroles, J. F., Sankararaman, S., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100722 · Cited by 19
Sakamoto, K., Kawamura, M., Watanabe, T., Ashidate, K., Kohro, T., Tanaka, A., Mori, Y., Tagami, M., Hirano, T., Yamazaki, T., et al. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0508-4 · Cited by 18
Dijk, W., & Cariou, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13636 · Cited by 19
Jia, X., Liu, J., Mehta, A., Ballantyne, C. M., & Virani, S. S. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07082-x · Cited by 18
Sabatine, M. S. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw572 · Cited by 18
Self-citationHepatocyte Rap1a contributes to obesity- and statin-associated hyperglycemia
Wang, Y., Spolitu, S., Zadroga, J. A., Sarecha, A. K., & Özcan, L. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111259 · Cited by 17
Wei, L., Gao, J., Wang, L., Tao, Q., & Tu, C. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad166 · Cited by 19
PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook
Bartolo, B. A. D., Scherer, D. J., Brown, A. D. H., Psaltis, P. J., & Nicholls, S. J. (2017) · BioDrugs · doi:10.1007/s40259-017-0220-y · Cited by 17
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review
Farnier, M. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1409115 · Cited by 17
Trinder, M., & Brunham, L. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000737 · Cited by 17
on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0545-2 · Cited by 16
Burger, A. L., Pogran, E., Muthspiel, M., Kaufmann, C. C., Jäger, B., & Huber, K. (2022) · Biomedicines · doi:10.3390/biomedicines10050970 · Cited by 17
Hay, R., Cullen, B., Graham, N., Lyall, D. M., Aman, A., Pell, J. P., Ward, J., Smith, D. J., & Strawbridge, R. J. (2022) · European Journal of Human Genetics · doi:10.1038/s41431-022-01107-9 · Cited by 16
Gouni‐Berthold, I., Schwarz, J., & Berthold, H. K. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01053-3 · Cited by 16
Elevated remnant cholesterol increase 6-year type 2 diabetes mellitus onset risk
Yuan, L., Liu, J., Huang, Z., Zhao, Y. W., Feng, Y., Yang, X., Hu, H., Zhang, J., Li, T.-Z., Li, Y., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117253 · Cited by 16
Luo, S., Zheng, M., Wong, V. W., & Yeung, S. L. A. (2024) · eGastroenterology · doi:10.1136/egastro-2024-100114 · Cited by 17
Sandor, C., Beer, N. L., & Webber, C. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005816 · Cited by 16
Henry, R. R., Müller‐Wieland, D., Taub, P. R., Bujas‐Bobanovic, M., Louie, M. J., Letierce, A., & Ginsberg, H. N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13273 · Cited by 16
Exploring Coronary Artery Disease GWAs Targets With Functional Links to Immunometabolism
Hughes, M., Lenighan, Y. M., Godson, C., & Roche, H. M. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00148 · Cited by 16
Wang, Z., Qiu, C., Xu, L., Zhao, L., Liu, Y., Wu, X., Wang, Q., Liu, W., Li, K., Deng, H., et al. (2020) · Molecular Genetics and Genomics · doi:10.1007/s00438-020-01651-3 · Cited by 16
LDL-Cholesterol-Lowering Therapy
Pirillo, A., Norata, G. D., & Catapano, A. L. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_361 · Cited by 17
Self-citationJoint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Moustafa, B., & Testai, F. D. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106057 · Cited by 15
Rosoff, D. B., Bell, A. S., Wagner, J., Mavromatis, L. A., Hamandi, A. M., Park, L. Y., Jung, J., & Lohoff, F. W. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.001 · Cited by 16
PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes
Grejtáková, D., Boroňová, I., Bernasovská, J., & Bellosta, S. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07599-5 · Cited by 20
Quiroga, B., Ramos, P. M., & Chiva, V. Á. (2020) · Nefrología · doi:10.1016/j.nefro.2020.04.020 · Cited by 16
Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients
Zenti, M. G., Lupo, M. G., Martin, S. D., Altomari, A., Galvan, S., Aventaggiato, M., Maneschi, C., Sandri, D., Paiola, E., Battistoni, M., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.07.013 · Cited by 16
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity
Moșteoru, S., Gaiță, D. I., & Banach, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1828343 · Cited by 15
Alghamdi, A. A., Balkhi, B. S., Altowaijri, A. I., Alshehri, N., Ralph, L., Marriott, E.-R., Urbich, M., Aljanad, F., & Aziziyeh, R. (2021) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00300-8 · Cited by 15
PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs
Roudaut, M., Idriss, S., Caillaud, A., Girardeau, A., Rimbert, A., Champon, B., David, A., Lévêque, A., Arnaud, L., Pichelin, M., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.10.004 · Cited by 15
Marchis, G. M. D., Dittrich, T. D., Malik, R., Zietz, A. V., Kriemler, L. F., Ference, B. A., Dichgans, M., & Georgakis, M. K. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.007 · Cited by 14
Self-citationMendelian randomisation in type 2 diabetes and coronary artery disease
Frayling, T. M., & Harlow, C. E. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.05.010 · Cited by 16
Wang, Z., Liu, M., Zhou, Y., Shao, H., Yang, D., Huang, Y., & Deng, W. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.990569 · Cited by 16
Depletion of loss-of-function germline mutations in centenarians reveals longevity genes
Ying, K., Castro, J. P., Shindyapina, A. V., Tyshkovskiy, A., Moqri, M., Goeminne, L. J. E., Milman, S., Zhang, Z. D., Barzilai, N., & Gladyshev, V. N. (2024) · Nature Communications · doi:10.1038/s41467-024-52967-2 · Cited by 14
Schwartz, G. G., Szarek, M. J., Jukema, J. W., Cobbaert, C. M., Reijnders, E., Bittner, V., Schwertfeger, M., Bhatt, D. L., Fazio, S., Garon, G., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2110 · Cited by 14
Self-citationClinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
Dixon, D. L., Buckley, L. F., Trankle, C. R., Kadariya, D., & Abbate, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114091 · Cited by 12
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
Ciccarelli, G., D’Elia, S., Paulis, M. D., Golino, P., & Cimmino, G. (2018) · Diseases · doi:10.3390/diseases6010022 · Cited by 14
Key aspects of PCSK9 inhibition beyond LDL lowering
Ramin‐Mangata, S., Blanchard, V., & Lambert, G. C. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000551 · Cited by 14
PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study
Lyall, D. M., Ward, J., Banach, M., Smith, G. D., Gill, J. M. R., Pell, J. P., Holmes, M. V., & Sattar, N. A. (2021) · Archives of Medical Science · doi:10.5114/aoms/127226 · Cited by 15
Kim, J., Neary, M. T., Aschard, H., Palakkamanil, M. M., Do, R., Wiggs, J. L., Khawaja, A. P., Pasquale, L. R., & Kang, J. H. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.5.31 · Cited by 14
PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
Pokrywka, G. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1436843 · Cited by 13
Alkhalil, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180816141827 · Cited by 14
The promise and reality of therapeutic discovery from large cohorts
Melamud, E., Taylor, D. L., Sethi, A., Cule, M., Baryshnikova, A., Saleheen, D., van Bruggen, N., & FitzGerald, G. A. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129196 · Cited by 14
Vaccination to prevent atherosclerotic cardiovascular diseases
Laufs, U., & Ference, B. A. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx302 · Cited by 14
Self-citationBrinton, E. A. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316893 · Cited by 14
Tomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
Dang, X., Liu, J., Zhang, Z., & Luo, X. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03160-3 · Cited by 12
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues
Şener, Y. Z., & Tokgözoğlu, L. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01918-2 · Cited by 13
Sagris, D., Ntaios, G., & Milionis, H. J. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329149 · Cited by 13
Atia, A., Aboeldahab, H. A., Wageeh, A., Elneny, M., Elmallahy, M., Elawfi, B., Aboelkhier, M. M., Elrosasy, A., Abdelwahab, M. M., Sayed, S., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00621-5 · Cited by 13
Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases
Ko, D. S., & Kim, Y. H. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.3.280 · Cited by 13
Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study
Ciofani, J. L., Han, D., Rao, K., Gill, D., Woolf, B. A. R., Rahimi, K., Allahwala, U. K., & Bhindi, R. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae092 · Cited by 13
Genetic Predisposition to Low-Density Lipoprotein Cholesterol and Incident Type 2 Diabetes
Ravi, A., Koyama, S., Cho, S. M. J., Haidermota, S., Hornsby, W., Ellinor, P. T., & Natarajan, P. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2024.5072 · Cited by 13
Cho, K. I., Kim, B. H., Park, Y. H., Ahn, J.-C., Kim, S., Chung, W., Kim, W., Sohn, I. S., Shin, J., Kim, Y. J., et al. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.05.007 · Cited by 13
Molecular and cellular biology of PCSK9: impact on glucose homeostasis
Tcheoubi, S. E. R., Akpovi, C. D., Coppée, F., Declèves, A., Laurent, S., Agbangla, C., & Burtéa, C. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2092622 · Cited by 13
Deshmukh, A. B., Bai, S., Aarthy, T., Kazi, R. S., Banarjee, R., Rathore, R., Vijayakumar, M. V., Thulasiram, H. V., Bhat, M. K., & Kulkarni, M. J. (2017) · Molecular BioSystems · doi:10.1039/c7mb00305f · Cited by 15
Precision Medicine and Cardiovascular Health: Insights from Mendelian Randomization Analyses
Spiller, W., Jung, K. J., Lee, J., & Jee, S. H. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0293 · Cited by 13
Management of Hyperlipidemia After Stroke
Brooks, D. C., & Schindler, J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0774-8 · Cited by 13
Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
Stein, E. A., & Turner, T. A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1348231 · Cited by 13
Integrating genetic data with biological insight: A practical guide to cis-Mendelian randomization
Karhunen, V., Woolf, B. A. R., Bhatnagar, P., Gill, D., & Burgess, S. (2026) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2026.03.011 · Cited by 13
Rap1 in the Context of PCSK9, Atherosclerosis, and Diabetes
Agarwal, H., Tinsley, B., Sarecha, A. K., & Özcan, L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01162-7 · Cited by 12
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
Holmes, M. V., Kartsonaki, C., Boxall, R., Lin, K., Reeve, N. F., Yu, C., Lv, J., Bennett, D., Hill, M., Yang, L., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae009 · Cited by 13
Povsic, T. J., Scott, R. C., Mahaffey, K. W., Blaustein, R. O., Edelberg, J. M., Lefkowitz, M. P., Solomon, S. D., Fox, J. C., Healy, K. E., Khakoo, A. Y., et al. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6739-9 · Cited by 12
Proprotein convertase subtilisin/kexin type 9
Stoekenbroek, R. M., & Kastelein, J. J. P. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000517 · Cited by 14
Annemans, L., Stock, J. K., & Chapman, M. J. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.07.005 · Cited by 12
Self-citationImpact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats
Momtazi‐Borojeni, A. A., Jaafari, M. R., Abdollahi, E., Banach, M., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4757170 · Cited by 13
Liu, L., Sheng, C., Lyu, Z., Dai, H., & Chen, K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.755834 · Cited by 12
Address Cardiovascular Health in Middle Age
Fuster, V., & Ibáñez, B. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.004 · Cited by 12
Zhou, H., Liu, W., Lv, Y., Liu, K., Wang, Y., Meng, S., Kang, T., Bao, Y., & Meng, H. (2023) · Nutrients · doi:10.3390/nu15040973 · Cited by 12
Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Marouf, B. H., Iqbal, Z., Mohamad, J. B., Bashir, B., Schofield, J. D., Syed, A. A., Kilpatrick, E. S., Stefanutti, C., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.12.005 · Cited by 12
Cai, T., Xu, X., Dong, L., Liang, S., Xin, M., Wang, T., Li, T., Wang, X., Zheng, W., Wang, C., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29168 · Cited by 11
Hong, S., Lee, Y., Kang, W. C., Hong, B., Lee, J., Lee, J., Yang, T., Yoon, J., Lee, S., Ahn, C., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02386-w · Cited by 12
Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy
Nicholls, S. J., & Nelson, A. J. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01280-4 · Cited by 12
Wang, L., Jiang, F., Sun, J., Zhao, J., He, Y., Gill, D., Burgess, S., Larsson, S. C., Yuan, S., & Li, X. (2025) · International Journal of Epidemiology · doi:10.1093/ije/dyaf020 · Cited by 11
Obicetrapib and its impact on lipid parameters: A comprehensive meta-analysis of the latest evidence
Bhatti, M. I., Safiullah, M., Farhan, K., Ali, A., Abdullah, S., Ali, A., & Ahmed, R. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.003 · Cited by 11
The future of epidemiology: methods or matter?
Ebrahim, S. B. J., Ferrie, J. E., & Smith, G. D. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyx032 · Cited by 13
Association of PCSK9 Loss-of-Function Variants With Risk of Heart Failure
Trudsø, L. C., Ghouse, J., Ahlberg, G., Bundgaard, H., & OLESEN, M. S. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.4798 · Cited by 10
Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
Park, S., Kim, S. G., Lee, S., Kim, Y., Cho, S., Kim, K., Kim, Y. C., Han, S. S., Lee, H., Lee, J. P., et al. (2023) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.237 · Cited by 11
Metadata
- Authors
- Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., & Sabatine, M. S.
- Affiliations
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12
- Volume
- 375
- Issue
- 22
- Pages
- 2144-2153
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2557654447
- Cited by
- 743
- References
- 39
- Citations by year
- 2026: 38 · 2025: 55 · 2024: 77 · 2023: 64 · 2022: 74 · 2021: 76 · 2020: 75 · 2019: 86 · 2018: 97 · 2017: 92 · 2016: 8
- FWCI
- 104.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Bristol Research (University of Bristol) (submittedVersion, other-oa)
- Funders
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PCSK9, HMGCR, LDL cholesterol, cardiovascular disease, diabetes mellitus, genetic variants, PCSK9 inhibitors, statins, genetic score, impaired fasting glucose, additive genetic effects, cardiovascular risk prediction, LDL-C lowering therapy, HMG-CoA reductase inhibition, cardiovascular events, diabetes risk
- MeSH terms
- Proprotein Convertase 9, Cardiovascular Diseases, Diabetes Mellitus, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Cholesterol, LDL, Male, Middle Aged, Random Allocation, Risk, Genetic Variation, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
